Montag A & Associates Inc. Has $1.23 Million Holdings in Stryker Co. (SYK)

Montag A & Associates Inc. boosted its holdings in shares of Stryker Co. (NYSE:SYK) by 152.1% during the 1st quarter, Holdings Channel reports. The firm owned 6,244 shares of the medical technology company’s stock after purchasing an additional 3,767 shares during the quarter. Montag A & Associates Inc.’s holdings in Stryker were worth $1,233,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Parallel Advisors LLC boosted its position in Stryker by 17.8% during the 1st quarter. Parallel Advisors LLC now owns 5,951 shares of the medical technology company’s stock worth $1,175,000 after acquiring an additional 901 shares during the period. Moors & Cabot Inc. boosted its position in Stryker by 86.6% during the 1st quarter. Moors & Cabot Inc. now owns 17,436 shares of the medical technology company’s stock worth $3,454,000 after acquiring an additional 8,091 shares during the period. Alps Advisors Inc. acquired a new position in Stryker during the 1st quarter worth $417,000. Kidder Stephen W acquired a new position in Stryker during the 1st quarter worth $271,000. Finally, Benedict Financial Advisors Inc. boosted its position in Stryker by 1.1% during the 1st quarter. Benedict Financial Advisors Inc. now owns 5,235 shares of the medical technology company’s stock worth $1,034,000 after acquiring an additional 57 shares during the period. Institutional investors own 74.68% of the company’s stock.

A number of research analysts have issued reports on SYK shares. SunTrust Banks boosted their price target on Stryker to $205.00 and gave the stock a “positive” rating in a research report on Monday, February 4th. Royal Bank of Canada boosted their price target on Stryker from $184.00 to $204.00 and gave the stock an “outperform” rating in a research report on Monday, March 11th. Credit Suisse Group upgraded Stryker to an “outperform” rating in a research report on Thursday, January 31st. Wells Fargo & Co boosted their price target on Stryker from $214.00 to $219.00 and gave the stock an “outperform” rating in a research report on Monday, April 1st. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $205.00 price target on shares of Stryker in a research report on Friday, March 1st. Six investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Stryker currently has a consensus rating of “Buy” and a consensus price target of $196.89.

In other news, COO Timothy J. Scannell sold 4,666 shares of the company’s stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $186.25, for a total transaction of $869,042.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Michael Damon Hutchinson sold 15,995 shares of the company’s stock in a transaction on Friday, February 8th. The shares were sold at an average price of $180.49, for a total value of $2,886,937.55. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 124,845 shares of company stock valued at $23,752,941. 7.20% of the stock is currently owned by company insiders.

Shares of Stryker stock opened at $187.15 on Wednesday. The company has a quick ratio of 1.30, a current ratio of 2.12 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $70.47 billion, a PE ratio of 25.60, a PEG ratio of 2.32 and a beta of 0.84. Stryker Co. has a fifty-two week low of $144.75 and a fifty-two week high of $199.85.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, April 23rd. The medical technology company reported $1.88 EPS for the quarter, beating the consensus estimate of $1.84 by $0.04. Stryker had a return on equity of 26.72% and a net margin of 25.38%. The business had revenue of $3.52 billion during the quarter, compared to the consensus estimate of $3.51 billion. During the same period in the prior year, the business posted $1.68 earnings per share. Stryker’s revenue was up 8.5% compared to the same quarter last year. Equities analysts anticipate that Stryker Co. will post 8.15 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 1.11%. The ex-dividend date of this dividend is Thursday, June 27th. Stryker’s dividend payout ratio is 28.45%.

TRADEMARK VIOLATION NOTICE: This story was first reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/05/08/montag-a-associates-inc-has-1-23-million-holdings-in-stryker-co-syk.html.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Recommended Story: Strike Price

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.